| Price | $12.75 |
| Year Range | $10.67 – $17.84 |
| Market Cap | $1.72B |
| Industry | Biotechnology |
What Is Intellia Therapeutics’s AI Stock Analysis?
Intellia Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Intellia Therapeutics’s momentum in near-real time.
Intellia Therapeutics (NTLA) has an AltIndex AI Score of 43/100, currently a Hold signal. The AI Score distills Intellia Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Intellia Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Intellia Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving NTLA’s AI Score?
Fundamentals
Revenue for the last quarter was $7.7M. This represents a decrease of 49.10% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 46.23%, which may be a cause for concern. Net income for the last quarter was $-107M. This represents a decrease of 10.81% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 5.31%, which may be a cause for concern. Ebitda for the last quarter was $-105M. This represents a decrease of 11.17% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 5.82%, which may be a cause for concern. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Intellia Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $12.75. This is an increase of 0.08% compared to a month ago, indicating a positive short-term trend. However, compared to a year ago, there is a decrease of 37.93%, which could be a cause for long-term concern. The trend is bullish. The current SMA10 is $12.07, which is higher than the previous SMA10 of $11.97. This indicates a potential upward trend in price movement. The RSI is 77.8, indicating a potentially overbought (bearish) condition.
See the full technical analysis and price prediction.
Alternative data
Intellia Therapeutics has an estimated 17 open positions. This number is down by -60% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Intellia Therapeutics is low (an estimate of only 33% of employees have a positive outlook), a concerning sign. Intellia Therapeutics has an estimate of 25,000 visitors to their webpage. The number of visitors is down by -31% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Intellia Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Intellia Therapeutics has 1,400 followers on their Instagram page, with no meaningful increase or decrese in the last couple of months. Intellia Therapeutics has 12,000 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Intellia Therapeutics’s market sentiment.
Frequently Asked Questions: Intellia Therapeutics AI Stock Analysis
Intellia Therapeutics's AltIndex AI Score is 43/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Intellia Therapeutics a Hold (43/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Intellia Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the NTLA AI Score or sign up to read the full thesis.
